As of March 31, 2026, BioRegenx, Inc has 969.02M shares outstanding.
| Shares Outstanding | 969.02M |
As of March 31, 2026, BioRegenx, Inc maintains a current ratio of 0.05, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -47.77, indicating conservative leverage, while an interest coverage ratio of -3.39 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.05 |
| Quick Ratio | 0.02 |
| Debt / Equity | -47.77 |
| Debt / EBITDA | -2.11 |
| Interest Coverage | -3.39 |
These figures cover the twelve months ended March 31, 2026. Return on assets (ROA) is negative at -317.96, reflecting losses generated across the asset base. The company generates approximately 321,007.45 in revenue per employee across its workforce of 5.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.74 indicates how many times BioRegenx, Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Assets (ROA) | -317.96 |
| Revenue Per Employee | 321,007.45 |
| Employee Count | 5.50 |
| Inventory Turnover | 2.74 |
As of the close on November 4, 2026, BioRegenx, Inc's stock has declined approximately 99.00% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.01.
| 52-Week Price Change | -99.00% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.01 |
Over the twelve months ended March 31, 2026, BioRegenx, Inc generated 1.77M in revenue and converted that into -1.30M in net income, yielding earnings per share of 0.00. EBITDA reached -1.03M, while operating income came in at -374,788.00.
| Revenue | 1.77M |
| Gross Profit | 1.45M |
| Operating Income | -374,788.00 |
| Pretax Income | -1.30M |
| Net Income | -1.30M |
| EBITDA | -1.03M |
| EBIT | -1.10M |
As of March 31, 2026, BioRegenx, Inc holds 45,806.00 in cash and equivalents against 2.17M in total debt, resulting in a net debt position of 2.12M. Total book value stands at -4.53M, with working capital of -3.80M providing operational flexibility.
| Cash & Cash Equivalents | 45,806.00 |
| Total Debt | 2.17M |
| Net Debt | 2.12M |
| Equity (Book Value) | -4.53M |
| Working Capital | -3.80M |
BioRegenx, Inc produced 27,906.00 in operating cash flow over the twelve months ended March 31, 2026. After subtracting -59,057.00 in capital expenditures, free cash flow totaled -31,151.00 - equivalent to 0.00 per share.
| Operating Cash Flow | 27,906.00 |
| Capital Expenditures | -59,057.00 |
| Free Cash Flow | -31,151.00 |
Over the twelve months ended March 31, 2026, BioRegenx, Inc posted a gross margin of 81.90, reflecting its pricing power and cost economics. The operating margin of -21.23 and net profit margin of -73.81 provide insight into operational efficiency.
| Gross Margin | 81.90 |
| Operating Margin | -21.23 |
| Pretax Margin | -73.81 |
| Profit Margin | -73.81 |
| EBITDA Margin | -58.08 |
BioRegenx, Inc's most recent stock split took place on March 25, 2011 with a 30:1 split ratio.
| Last Split Date | 3/25/2011 |
| Split Ratio | 30:1 |